For the first time in history, a patient has survived more than eight months following a gene-edited pig organ transplant, marking a pivotal moment as xenotransplantation moves from experimental promise toward clinical reality. With biotech companies now cleared by the FDA to initiate clinical trials, the field is advancing at unprecedented speed. This panel brings together scientific, clinical, and industry leaders to examine the data guiding first-in-human xenotransplant studies, how advances in genome engineering are addressing immune rejection and viral risk, and what it will take to translate early success into safe, scalable clinical practice. As transplantation enters a new era, the discussion will explore not only how xenotransplantation could alleviate the global organ shortage, but how it may ultimately redefine long-term patient care.